Intercept Pharmaceuticals : EASL 2023 Podium Presentation of OCA-bezafibrate Combination Planned Interim Analysis
Results from a planned interim analysis of a randomized, double- blind, active-controlled trial evaluating the effects of obeticholic acid and bezafibrate on serum biomarkers in primary biliary cholangitis ...
Source: marketscreener.com